Muhammad A Khattak

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-I...

Vibostolimab-pembrolizumab versus pembrolizumab als adjuvante therapie bij hoogrisico stadium IIB-melanoom

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossove...

Adjuvant pembrolizumab versus placebo bij stadium IIB/IIC melanoom: KEYNOTE-716 definitieve analyse

QoL bij adjuvant pembrolizumab bij stadium II melanoom: KEYNOTE-716 analyse

Adjuvant pembrolizumab bij stadium IIB/IIC melanoom: KEYNOTE-716 tweejaars definitief

Adjuvant pembrolizumab versus placebo bij stadium IIB/IIC melanoom: KEYNOTE-716 fase III